Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07219420 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Study acronym: BeSeen
StatusRecruiting
PhasePhase 3
Started2025-11-14
View on ClinicalTrials.gov ↗

Amendment history

2026-08-26
Study Status, Contacts/Locations v14
Trial sites expanded: 87 → 91 locations
2026-07-16
Study Status, Contacts/Locations v13
Study sites85→87
2026-07-02
Study Status, Contacts/Locations v12
Trial sites expanded: 77 → 85 locations
2026-06-18
Study Status, Contacts/Locations v11
Trial sites expanded: 74 → 77 locations
2026-06-04
Study Status, Contacts/Locations v10
Trial sites expanded: 41 → 74 locations
Show 9 earlier versions
2026-05-26
Study Status, Study Design, Outcome Measures v9
Enrollment target300→320
Secondary endpointsdetails revised at 4 of 10 entries
2026-04-07
Study Status, Study Design, Outcome Measures, Eligibility v8
Enrollment target320→300
Eligibility criteria-13 characters
[...] efined as pustule severity ≥2 and having more than 5 active white-yellow pustules Participant must be a candidate for systemic therap [...]
Secondary endpointsdetails revised at 3 of 10 entries
2026-03-12
Study Identification, Study Status, Study Design, Outcome Measures, Eligibility, Contacts/Locations v7
Enrollment target300→320
Study sites28→41
Eligibility criteria+13 characters
[...] efined as pustule severity ≥2 and having more than 5 active white-yellow pustules Participant must be a candidate for systemic therap [...]
Secondary endpointsdetails revised at 3 of 10 entries
2026-02-26
Study Status, Contacts/Locations v6
Completion date2029-10-29→2029-11-22
Study sites22→28
2026-02-12
Study Status, Contacts/Locations v5
Study sites14→22
2026-01-28
Study Status, Contacts/Locations v4
Study sites6→14
2026-01-07
Study Status, Contacts/Locations v3
Study sites4→6
2025-12-02
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-11→confirmed 2025-11-14
Study sites0→4
2025-11-12
Study Status v1
Start date2025-11-03→2025-11
2025-10-17
Original filing
UCB Biopharma SRL
68 trials monitored
See 4 trials at risk
Psoriasis
418 trials monitored
See 17 trials at risk
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
Trial Details
NCT Number NCT07219420
Lead Sponsor UCB Biopharma SRL
Conditions Palmoplantar Pustulosis
Enrollment 320 participants
Start Date 2025-11-14
Primary Completion 2027-12-27 (estimated)
Study Completion 2029-11-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-27